<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02046291</url>
  </required_header>
  <id_info>
    <org_study_id>2012LS089</org_study_id>
    <secondary_id>MT2012-17R</secondary_id>
    <nct_id>NCT02046291</nct_id>
  </id_info>
  <brief_title>Safety of Romiplostim (Nplate®) Following UCBT</brief_title>
  <official_title>Safety of Romiplostim (Nplate®) in Patients Who Have Failed to Achieve Platelet Engraftment Following Umbilical Cord Blood Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single institution, phase I dose escalation study of weekly romiplostim post&#xD;
      umbilical cord blood transplantation in patients who fail to achieve platelet engraftment by&#xD;
      day +30. Engraftment is defined as a platelet count ≥ 20 x 109/L on 3 consecutive&#xD;
      measurements without transfusion for 7 days. Romiplostim is administered at the assigned dose&#xD;
      as 6 weekly injections beginning by day +42 post transplant. Up to 4 dose levels (4, 6, 8,&#xD;
      and 10 mcg/kg/dose) will be evaluated with the maximum tolerated dose (MTD) of romiplostim&#xD;
      determined by using the Continual Reassessment Method (CRM). The goal of this CRM will be to&#xD;
      identify 1 of the 4 dose levels which corresponds to the desired maximum toxicity rate of 20%&#xD;
      or less.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2015</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">December 12, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of romiplostim</measure>
    <time_frame>Day +28 blood transplant (UCBT)</time_frame>
    <description>Measured by number of patients who have failed to achieve platelet engraftment by day +28 after a myeloablative or nonmyeloablative umbilical cord blood transplant (UCBT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet recovery</measure>
    <time_frame>Day +28</time_frame>
    <description>Average speed of platelet recovery in patients who have failed to achieve platelet engraftment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombocytopenia</measure>
    <time_frame>Day +28</time_frame>
    <description>Incidence of clinically significant bleeding episodes and number of platelet transfusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone marrow fibrosis</measure>
    <time_frame>Day 100 post transplant</time_frame>
    <description>Incidence of bone marrow fibrosis.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Romiplostim treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks (i.e. 6 doses) unless platelet count exceeds 100 x 10^9/L and at least 4 doses of therapy were given.After the initial dose, subsequent doses will be administered within a window of +/- 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romiplostim</intervention_name>
    <description>Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.</description>
    <arm_group_label>Romiplostim treatment</arm_group_label>
    <other_name>Nplate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient who has undergone a single or double umbilical cord blood transplant&#xD;
             (UCBT) except those with primary myelofibrosis.&#xD;
&#xD;
               -  Those with acute leukemia must be in remission at the time of transplant&#xD;
&#xD;
          -  Must have achieved neutrophil engraftment (defined as an ANC &gt;500 for three&#xD;
             consecutive days) and be off daily G-CSF prior to starting romiplostim. Intermittent&#xD;
             G-CSF is allowed.&#xD;
&#xD;
          -  Failure to achieve platelet engraftment (defined as platelet count ≥20x10^9/L on 3&#xD;
             consecutive measurements without transfusion for 7 days) by day +28 post UCBT&#xD;
&#xD;
          -  Between day +28 and day +42 status post myeloablative or nonmyeloablative UCBT (single&#xD;
             or double cord blood transplant)&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Adequate organ function within 7 days of enrollment defined as:&#xD;
&#xD;
               -  Creatinine: ≤ 2.0 mg/dL&#xD;
&#xD;
               -  Hepatic: SGOT and SGPT &lt; 5 x upper limit of institutional normal (ULN)&#xD;
&#xD;
          -  Women of child bearing potential agree to use effective contraception during therapy&#xD;
             and for 4 months after completion of therapy&#xD;
&#xD;
          -  Voluntary written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known pregnancy - Pregnancy Category C: there are no adequate and well-controlled&#xD;
             studies of romiplostim in pregnancy&#xD;
&#xD;
          -  Recurrence of AML or myelodysplastic syndrome on bone marrow evaluation done within 21&#xD;
             days of enrollment&#xD;
&#xD;
          -  Presence of clinically significant bone marrow fibrosis on the bone marrow examination&#xD;
             immediately prior to UCBT&#xD;
&#xD;
          -  Patients requiring more than one platelet transfusion per day&#xD;
&#xD;
          -  History of an allergy to romiplostim&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret MacMillan, MD, MSc, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2014</study_first_posted>
  <last_update_submitted>June 5, 2021</last_update_submitted>
  <last_update_submitted_qc>June 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>umbilical cord transplant</keyword>
  <keyword>acute leukemia</keyword>
  <keyword>UCBT</keyword>
  <keyword>Hodgkin's Lymphoma</keyword>
  <keyword>Lymphoid Leukemia</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Myeloid and Monocytic Leukemia</keyword>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>Hematopoietic malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

